News ImmuneRegen NewsImmuneRegen BioSciences Signs Material Transfer Agreement with Celgene Cellular TherapeuticsJanuary 23, 2008 6:30 AM ETImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. IRBO, today announced it has finalized a Material Transfer Agreement (MTA) with Celgene Cellular Therapeutics (CCT). As part of the agreement, ImmuneRegen will ship its potential therapeutic Homspera® to CCT for testing. Addressing existing complementary product pipelines; Celgene Cellular Therapeutics and ImmuneRegen are exploring opportunities to jointly pursue U.S. government funding in support of their rapid wound healing applications. CCT will perform testing of Homspera in order to evaluate the potential impact on cellular products in the company's development pipeline. ImmuneRegen believes that Homspera will modify stem/progenitor cell activity which would be of value in multiple therapeutic applications of interest to both companies. In early preclinical testing by ImmuneRegen, Homspera increased the number of white blood cells in circulation following radiation, which may indicate that Homspera can reduce the body's recovery time after radiation treatment for cancer or following unintentional radiation exposure in soldiers, industrial workers or civilians. Initial preclinical studies conducted by ImmuneRegen have also indicated Homspera's effect on the blood-forming tissues in bone marrow and on hematopoietic stem cells, which may also enable its use in the treatment of various cancers. Further, the intracellular mechanisms mediating Homspera activity following binding on cell surfaces have also been implicated in mechanisms governing gene expression and function, including those reported to be perturbed in many cancers and inflammatory states, including: the proteins regulating the transcription factor NF-kB, inflammatory and anti-inflammatory cytokines, interleukins, extracellular signal-regulated kinases 1 and 2 (ERK1/2), mitogen-activated protein kinases (MAPKs) and related kinases and phosphatases as well as associated functions such as receptor internalization, B-arrestin binding, receptor recycling and ubiquitination of internalized proteins. These systems are being probed by many pharmaceutical companies, including Celgene, in their search for potential drug candidates. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|